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ABSTRACT
Objective This study describes the influence of sex and 
disease phenotype on the occurrence of cardiac events in 
Fabry disease (FD).
Methods Cardiac events from birth to last visit (median 
age 50 years) were recorded for 213 patients with FD. 
Patients were categorised as follows : men with classical 
FD (n=57), men with non- classical FD (n=26), women 
with classical FD (n=98) and women with non- classical 
FD (n=32), based on the presence of classical FD 
symptoms, family history (men and women), biomarkers 
and residual enzyme activity (men). Event rates per 1000 
patient- years after the age of 15 years and median 
event- free survival (EVS) age were presented. Influence 
of disease phenotype, sex and their interaction was 
studied using Firth’s penalised Cox regression.
Results The event rates of major cardiovascular 
events (combined endpoint cardiovascular death (CVD), 
heart failure (HF) hospitalisation, sustained ventricular 
arrhythmias (SVAs) and myocardial infarction) were 11.0 
(95% CI 6.6 to 17.3) in men with classical FD (EVS 55 
years), 4.4 (95% CI 2.5 to 7.1) in women with classical 
FD (EVS 70 years) and 5.9 (95% CI 2.6 to 11.6) in men 
with non- classical FD (EVS 70 years). None of these 
events occurred in women with non- classical FD. Sex 
and phenotype significantly influenced the risk of major 
adverse cardiovascular event. CVD was the leading cause 
of death (75%) to which HF contributed most (42%). The 
overall rate of SVA was low (14 events in nine patients 
(4%)).
Conclusions Sex and phenotype greatly influence 
the risk and age of onset of cardiac events in FD. This 
indicates the need for patient group- specific follow- up 
and treatment.
INTRODUCTION
Fabry disease (FD) is a rare X- linked lysosomal 
storage disease that is caused by mutations in the 
Galactosidase alpha gene, resulting in reduced 
alpha- galactosidase A enzyme activity.1 2 Accu-
mulation of the enzyme’s substrate globotriaosyl-
ceramide (Gb3) and its derivatives is the primary 
trigger for damage and dysfunction of various 
tissues and organs, including vascular endothelium 
and the heart.3–5
Due to the X- linked mode of inheritance, men 
are generally more severely affected and disease 
manifestations occur earlier compared with 
women. In addition, a distinction is made between 
classical and non- classical disease phenotypes, with 
significant differences in onset and progression of 
symptoms, organ damage and outcome between 
these two groups. The classical form of FD in men 
is characterised by greatly reduced or absent alpha- 
galactosidase A activity, resulting in manifestations 
in multiple organs, starting from late adolescence.6 7 
Non- classical disease manifests itself later in adult-
hood and often affects only the heart.8–10
Early cardiac manifestations of FD are brady-
cardia, shortened PQ interval, low native T1 value 
on cardiac MRI and, in male patients and a subset 
of female patients, cardiac hypertrophy.11 12 As the 
disease progresses, conduction abnormalities (CAs), 
supraventricular arrhythmias, ischaemic heart 
disease, diastolic and systolic dysfunctions and ulti-
mately overt heart failure (HF), leading to cardiac 
death, may occur.3 13–22 On the other hand, a signif-
icant number of patients will remain asymptom-
atic, even at an advanced age.7 Limited evidence is 
available on the risk and timing of cardiac mani-
festations and events in different patient groups 
(ie, men vs women, classical vs non- classical FD 
phenotype).3 23 It is important to generate these 
data, as it will guide patient- specific follow- up and 
timing of treatment initiation, risk assessment (eg, 
for sudden cardiac death (SCD)) and evaluation 
of new FD therapies that are currently in various 
stages of development. To answer the open ques-
tions, we performed a retrospective study in an FD 
cohort under follow- up at the Amsterdam Univer-
sity Medical Centres (AUMC), which is unique in 
both its size, as well as the length of systematic 
follow- up of patients, providing detailed clinical 
data on cardiac outcome.
METHODS
Patient and public involvement
This is an observational longitudinal retrospective 
study, using data from all adult patients with a defi-
nite diagnosis of FD (figure 1) that have been under 
follow- up at any time at the AUMC, the national 
referral centre for patients with FD in the Nether-
lands (table 1).
Data collection
Patients were divided into four groups: men with 
classical FD, men with non- classical FD, women 
with classical FD and women with non- classical 
FD, based on the presence of classical FD symptoms 
(cornea verticillata, acroparesthesia or angiokera-
toma), family history or known mutation–pheno-
type associations (men and women) and biomarkers 
and residual alpha- galactosidase A activity (men)7 24 
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(see figure 1 for details). Patients attended the clinic for stan-
dardised follow- up visits.
Between September 2018 and January 2019, all available 
patients charts, clinical letters, cardiac imaging reports from 
birth until the last outpatient clinic visit were investigated 
to record the following events: cardiovascular death (CVD), 
HF hospitalisation, sustained ventricular arrhythmias (SVA), 
myocardial infarction (MI), CA, pacemaker or implantable 
cardiac defibrillator (ICD) implantation, atrial fibrillation, 
coronary artery disease (CAD), percutaneous coronary inter-
vention, coronary artery bypass graft surgery, systolic dysfunc-
tion on cardiac MRI or, if unavailable on echocardiography, 
left ventricular outflow tract (LVOT) obstruction, moderate 
or severe valve disease and other heart surgery/intervention. 
The combined endpoint major adverse cardiovascular event 
(MACE) was defined as the occurrence of at least one of the 
following events: CVD, HF hospitalisation, SVA or MI. SVA 
included SCD, sudden cardiac arrest, sustained ventricular 
tachycardia lasting >30 s, appropriate ICD shock, and ventric-
ular fibrillation. CA were defined as a composite of second- 
degree atrioventricular (AV) block type II, third- degree AV 
block, sinus arrest and device implantation for CA. Endpoint 
definitions are provided in online supplemental table 1). 
Events were adjudicated by a panel of experts consisting of 
Figure 1 Flowchart for the diagnosis and phenotype allocation in FD. CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leucoencephalopathy; CARASIL, cerebral autosomal recessive arteriopathy with subcortical infarcts and leucoencephalopathy; EM, electron 
microscopy; FD, Fabry disease; GLA, galactosidase alpha; IVSd, diastolic interventricular septum diameter.
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two cardiologists (AH and MB) and one metabolic specialist 
(ML).
Statistical analysis
For all cardiac events, the event rate per 1000 patient- years was 
calculated in order to correct for unequal follow- up duration 
between the different patient groups. The corresponding 95% 
CIs were reported for both individual and composite cardiac 
events, using the mid- P exact test (table 2 and online supple-
mental table 2). For the event rates calculation, follow- up dura-
tion from the age of 15 years onwards was used, because this 
study shows that cardiac events do not occur before the age 
of 15 years (figure 2, table 2 and online supplemental table 2) 
and the event- free follow- up duration of especially the younger 
men with classical FD would impact unevenly on the event rate 
without this correction.
Event- free survival (EVS) was analysed using the Kaplan- Meier 
(KM) method, in which patients where stratified according to 
phenotype and sex. If less than 50% of the patients developed 
a specific event, the median age of onset for those patients who 
experienced the event was reported instead. Pairwise compar-
ison between patients with FD groups was performed using a 
log- rank test, with Bonferroni correction. Next, these analysis 
were performed correcting for competing risks (CRs) (eg, non- 
CVD for the outcome of CVD, online supplemental figures 2–6). 
Cox regression analyses were performed to assess the effect of 
Table 1 Patient characteristics
All
Men Women
Classical Non- classical Classical Non- classical
General
  Number of patients, n (%) 213 (100) 57 (27) 26 (12) 98 (46) 32 (15)
  Age at last outpatient visit or death (years), median (range) 50 (19–83) 45 (19–66) 64 (26–78) 51 (19–83) 47 (23–79)
  Cumulative follow- up from the age of 15 (years) 7090 1546 1190 3213 1140
  Age at first outpatient clinic visit (years) median (range) 42 (3–77) 30 (3–58) 60 (22–70) 41 (7–71) 44 (19–77)
Comorbidities
  Number of patients with CVA at any time, n (%) 25 (12) 9 (16) 5 (19) 11 (11) 0 (0)
  Obesity,* n (%) 30/198 (15) 1/51 (2) 4/24 (17) 16/93 (17%) 9/30 (30)
  Smoking,* n (%) 75/177 (42) 17/44 (39) 14/23 (61) 35/87 (40) 9/23 (39)
  Hypertension,* n (%) 48/199 (24) 8/51 (16) 11/26 (42) 18/95 (19) 11/27 (41)
  Dyslipidaemia,* n (%) 14/187 (8) 0/43 (0) 7/23 (30) 5/91 (6) 2/30 (7)
  Diabetes mellitus,* n (%) 4/203 (2) 0/52 (0) 2/25 (8) 1/96 (1) 1/30 (3)
Cardiac imaging
Echocardiography
  Available echocardiography at any time, n (%) 181 (85) 49 (86) 21 (81) 87 (89) 24 (75)
  Left ventricular hypertrophy on echocardiography at any time, n (%)† 90/181 (50) 24/49 (49) 16/21 (76) 43/87 (49) 7/24 (29)
Cardiac MR‡
  Available cardiac MR at last follow- up, n (%) 141 (66) 41 (72) 11 (42) 71 (73) 18 (56)
  Left ventricular ejection fraction (%), median (range) 61 (24–84) 57 (24–70) 57 (48–67) 63 (51–84) 61 (57–70)
  Available cardiac MR, where myocardial fibrosis was assessed by late 
gadolinium enhancement, n (%)
139/141 (99) 39/41 (95) 11/11 (100) 71/71 (100) 18/18 (100)
  Myocardial fibrosis on cardiac MR, n (%) 54/139 (39) 13/39 (33) 6/11 (55) 29/71 (41) 6/18 (33)
ERT
  Patients on ERT, n (%) 128 (60) 47 (83) 12 (46) 62 (63) 7 (22)
  Age start ERT (years), median (range) 42 (10–77) 27 (10–58) 59 (20–68) 46 (16–71) 60 (30–77)
  Untreated patients, n (%) 85 (40) 10 (17) 14 (54) 36 (37) 25 (78)
Reasons for not starting ERT
  Diagnosis through family screening, absent or minimal organ 
involvement, n (%)
41 (19) 1 (2) 3 (12) 17 (17) 20 (63)
  Diagnosis not through family screening, absent or minimal organ 
involvement, n (%)
2 (1) 0 (0) 0 (0) 1 (1) 1 (3)
  Advanced disease stage, n (%) 18 (9) 2 (4) 9 (35) 5 (5) 2 (6)
  Follow- up ended before ERT was available, n (%) 8 (4) 5 (9) 0 (0) 3 (3) 0 (0)
  Other, n (%) 16 (8) 2 (4) 2 (8) 10 (10) 2 (6)
*Cardiovascular risk factors assessed at first outpatient clinic visit: obesity: Body Mass Index≥ 30 kg/m2; smoking: patients who have ever smoked; hypertension: 
antihypertensive medication use or systolic blood pressure of >140 mm Hg and/or diastolic blood pressure of >90 mm Hg, measured at least twice; dyslipidaemia: elevated levels 
of total cholesterol (>6.5 mmol/L) or low- density lipoprotein cholesterol (>2.5 mmol/L) or triglycerides (>3.0 mmol/L), or low levels of high- density lipoprotein cholesterol (men: 
<1.0 mmol/L, women: <1.2 mmol/L) or medication prescribed for the indication dyslipidaemia; diabetes mellitus: type 1 or type 2, if reported by a medical doctor in the medical 
chart or when the patient is using antidiabetic medication.
†The included cardiac MRIs were obtained at the time of the last follow- up (with a maximum range of 2 years between the MRI and the last follow- up date). Severely affected 
patients with Fabry disease with a non- MRI compatible cardiac device were not included in the routine imaging follow- up.
‡Definition of cardiac hypertrophy on echocardiography: men>51 g/m2.7 and women>48 g/m2.7), calculated with the Devereux formula: 0.8{1.04[([LVEDD+IVSd+PWd]3−
LVEDD3)]}+0.6. LVEDD, IVSd and PWd are in millimetre.
CVA, cerebrovascular accident; ERT, enzyme replacement therapy; IVSd, interventricular septal thickness at end diastole; LVEDD, left ventricular end diastolic dimension; MR, 
magnetic resonance; PWd, posterior wall thickness at end diastole.
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phenotype and sex and the interaction between these variables 
on the occurrence of events. Since no events occurred in the 
subgroup of women with non- classical FD, we used Firth’s 
penalised Cox regression to obtain stable models. P values of 
<0.008 (after Bonferroni correction) were considered statisti-
cally significant. SPSS V.25 and R V.3.6.1 were used for statistical 
analysis.
RESULTS
A total of 213 patients were included: 57 (27%) men and 98 
(46%) women with classical FD, and 26 (12%) men and 32 (15%) 
women with non- classical FD. The median age at last outpatient 
visit or death was 50 years (range 19–83). Patient characteris-
tics are described in table 1. Figure 2 shows the occurrence of 
cardiac events for all patients in the four different groups.
Enzyme replacement therapy (ERT)
Sixty per cent (128/213) of the included patients were treated 
with ERT. Decisions to initiate treatment were based on the 
presence of symptoms as described earlier25 or based on the 
recommendations of the European Fabry Working Group once 
they became available.26 The majority of the untreated patients 
Table 2 Prevalence, event rates and age at onset of death and cardiovascular events
All (N=213)









  Number of patients, n (%) 24 (11) 15 (26) 3 (12) 6 (6) 0 (0)
  Deaths per 1000 person- years (from the age of 15 years), with 95% CI 3.4 (2.2 to 5.0) 9.7 (5.7 to 15.6) 2.5 (0.6 to 6.9) 1.9 (0.8 to 3.9) 0 (–)
  Age at death (years), median (range) 58 (26–77) 56 (26–66) 65 (64–68) 72 (57–77) (–)
  Cause of death: HF, n (%) 10 (42) 4 (27) 2 (67) 4 (67) 0 (0)
  Cause of death: MI, n (%) 2 (8) 2 (13) 0 (0) 0 (0) 0 (0)
  Cause of death: ischaemic or haemorrhagic cerebrovascular accident, n (%) 4 (17) 2 (13) 0 (0) 2 (33) 0 (0)
  Cause death: SCD during haemodialysis 2 (8) 2 (13) 0 (0) 0 (0) 0 (0)
  Cause death: other, n (%) 6 (25) 5 (33) 1 (33) 0 (0) 0 (0)
Major adverse cardiovascular events*
  Number of patients, n (%) 38 (18) 17 (30) 7 (27) 14 (14) 0 (0)
  Event rate, with 95% CI 5.4 (3.9 to 7.3) 11.0 (6.6 to 
17.3)
5.9 (2.6 to 11.6) 4.4 (2.5 to 7.1) 0 (–)
  Age at first event (years) 54 (33–75) 52 (33–66) 64 (34–67) 54 (34–75) (–)
CVD
  Number of patients, n (%) 18 (9) 10 (18) 2 (8) 6 (6) 0 (0)
  Event rate, with 95% CI 2.5 (1.6 to 3.9) 6.5 (3.3 to 11.5) 1.7 (0.3 to 5.6) 1.9 (0.8 to 3.9) 0 (–)
  Age at CVD (years) 58 (47–77) 55 (47–66) 66 (65–68) 72 (57–77) (–)
HF hospitalisation
  Number of patients, n (%) 18 (9) 8 (14) 4 (15) 6 (6) 0 (0)
  Event rate, with 95% CI 2.5 (1.6 to .9) 5.2 (2.4 to 9.8) 3.4 (1.1 to 8.1) 1.9 (0.8 to 3.9) 0 (–)
  Age at first event (years) 63 (43–77) 54 (43–66) 68 (64–69) 69 (52–77) (–)
SVAs†
  Number of patients, n (%) 9 (4) 4 (7) 3 (12) 2 (2) 0 (0)
  Event rate, with 95% CI 1.3 (0.6–2.3) 2.6 (0.8–6.2) 2.5 (0.6–6.9) 0.6 (0.1–2.6) 0 (–)
  Age at first event (years) 56 (46–73) 48 (46–56) 67 (64–67) 62 (51–73) (–)
MI
  Number of patients, n (%) 22 (10) 8 (14) 4 (15) 10 (10) 0 (0)
  Event rate, with 95% CI 3.1 (2.0 to 4.6) 5.2 (2.4 to 9.8) 3.4 (1.1 to 8.1) 3.1 (1.6 to 5.6) 0 (–)
  Age at first event 51 (33–75) 51 (33–58) 57 (34–67) 51 (34–75) (–)
CAs‡
  Number of patients, n (%) 29 (14) 7 (12) 8 (50) 12 (12) 2 (6)
  Event rate, with 95% CI 4.1 (2.8 to 5.8) 4.5 (2.0 to 9.0) 6.7 (3.1 to 12.8) 3.7 (2.0 to 6.4) 1.8 (0.3 to 5.8)
  Age at first documentation (years) 60 (48–74) 56 (48–60) 62 (50–65) 63 (49–74) 72 (71–72)
Atrial fibrillation
  Number of patients, n (%) 44 (21) 20 (35) 7 (27) 16 (16) 1 (3)
  Event rate, with 95% CI 6.2 (4.6 to 8.3) 12.9 (8.1 to 
19.6)
5.9 (2.6 to 11.6) 5.0 (3.0 to 7.9) 0.9 (0.04 to 4.3)
  Age at first event (years) 55 (18–69) 49 (18–61) 57 (34–69) 58 (47–67) 68 (–)
Data are presented as number (percentage) or median (range). All event rates are per 1000 patient- years from the age of 15 years onwards.
*Major adverse cardiac events: composite of CVD, HF hospitalisation, SVAs and MI.
†SVAs: composite of SCD, sudden cardiac arrest, sustained ventricular tachycardia, including appropriate ICD shock, and ventricular fibrillation.
‡CAs: composite of second- degree AV block Mobitz II, third- degree AV block, sinus arrest and pacemaker or ICD device implantation for CAs.
AV, atrioventricular; CA, conduction abnormality; CVD, cardiovascular death; HF, heart failure; ICD, implantable cardiac defibrillator; MI, myocardial infarction; SCD, sudden cardiac 
death.
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were either diagnosed through family screening, without signs 
of organ involvement at the last follow- up (48% of untreated 
patients) or diagnosed at an advanced disease stage, at which 
point no benefit of ERT was to be expected (21%) (table 1).
Major adverse cardiovascular events
The event rate (after age 15 years) for MACE was 11.0 per 1000 
patient- years (95% CI 6.6 to 17.3) for men with classical FD vs 
4.4 (95% CI 2.5 to 7.1) in women with classical FD and 5.9 (95% 
CI 2.6 to 11.6) in men with non- classical FD. None of the women 
with non- classical FD developed MACE. KM analysis showed a 
Figure 2 Occurrence of cardiac events for all 213 patients with FD, stratified by sex and phenotype. Included events are death, CVD, HF 
hospitalisation (first event), SVAs (first event), MI (first event), CA (first recorded) and AF (first recorded). No event was scored if none of the 
predefined events was recorded at the time of the last outpatient visit. ♂, men; ♀, women; AF, atrial fibrillation; CA, conduction abnormality; CVD, 
cardiovascular death; HF, heart failure; MI, myocardial infarction; SVA, sustained ventricular arrhythmia.
Figure 3 Kaplan- Meier curves (with 95% CIs) including data of 213 patients with FD, stratified by sex and phenotype, for major adverse 
cardiovascular events (clustered endpoint of cardiovascular death, heart failure hospitalisation, sustained ventricular arrhythmias and myocardial 
infarction). Patients are censored if a MACE did not occur at the time of the last follow- up contact. Median event- free survival is given for each group. 
Pairwise comparisons between patient groups are given. FD, Fabry disease.
 on F
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significant difference between the four subgroups (figure 3; see 
online supplemental figure 2 for CR analysis). Having a clas-
sical phenotype and being male significantly increased the risk 
of MACE (table 3). HR for MACE in men with a classical versus 
non- classical phenotype was 6.1 (95% CI 2.4-17.0), and that in 
men vs women with a classical disease phenotype was 5.0 (95% 
CI 2.3-11.0) (table 4). Of the patients who developed MACE, 
MI was the first recorded event in 47% of men with classical 
FD, 64% of women with classical FD and 57% of men with 
non- classical FD. Excluding MI from the MACE analysis did not 
change the observed differences between the patient groups (see 
online supplemental results).
Cardiovascular death
In men with classical FD, 10 out of 15 deaths (67%) were CVDs 
(event rate 6.5 per 1000 patient years). CVD was also the major 
cause of death in women with classical FD (6/6 deaths (100%), 
event rate 1.9) and men with non- classical FD (2/3 deaths (67%), 
event rate 1.7). KM analysis showed a significant difference 
between the four subgroups (figure 4A; see online supplemental 
figure 3 for CR analysis). Having a classical phenotype increased 
the risk of CVD, but this effect did not hold after correcting for 
multiple testing (table 3). Group comparisons showed signifi-
cant higher risk in men with classical versus non- classical disease 
(HR: 22.2, 95% CI: 5.0-19.3) and men versus women with clas-
sical disease (HR: 14.8, 95% CI: 4.3-67.0) (table 4). HF was an 
important cause of CVD (40% of CVD in men with classical FD, 
67% in women with classical FD and 100% in men with non- 
classical FD) (table 2 and online supplemental table 2).
HF hospitalisation
The event rate for HF hospitalisation was 5.2 in men with 
classical FD vs 1.9 in women with classical FD. In men with 
non- classical FD, the event rate was 3.4. KM analysis showed 
a significant difference between the four subgroups (figure 4B; 
see online supplemental figure 4 for CR analysis). Classical 
phenotype and male sex increased the risk of HF hospitalisation, 
but this effect did not hold after correcting for multiple testing 
(table 3). Group comparisons showed significant higher risk in 
men with classical versus non- classical disease (HR: 15.5, 95% 
CI: 3.7-82.7) and men versus women with classical disease (HR: 
15.4, 95% CI: 4.1-73.8) (table 4). The left ventricle ejection 
fraction prior or at the time of the event was known in 17 out 
of 18 patients, who were hospitalised because of HF. In 12/17 
patients (71%), the ejection fraction was <50% (5/7 in men with 
classical FD, 3/6 in women with classical FD and 4/4 in men with 
non- classical FD).
SVAs and ICD device implantation
The event rate of SVA was low (14 events in nine patients in the 
total cohort) (figure 4C; see online supplemental figure 5 for 
CR analysis; for between- group comparison, see tables 3 and 
4). The first SVA episode occurred at the time of an MI in two 
patients and in one patient at the time of HF hospitalisation. Of 
the remaining six patients who experienced an SVA, two had 
an ejection fraction of <35%; in two patients, the first event 
occurred during haemodialysis, and in one patient, an allergic 
reaction to clopidogrel was described as a possible trigger. In the 
last patient, no trigger could be identified. Of all patients who 
suffered SVA, three died as a result of the first episode (one due 
to MI and two during haemodialysis); one patient died 3 years 
after the first SVA episode due to MI. The other five patients had 
an ICD implanted after the first event. In three patients, the ICD 
successfully aborted an episode of ventricular arrhythmia during 
follow- up. Of these three patients, two died of HF, respectively, 
22 months and 6 years after ICD implantation. One patient was 
alive at the last follow- up (ICD was 4.8 years in situ). In two 
patients, no shocks were administered by the ICD. Of these two, 
one patient died 9 months after ICD implantation as a result 
of HF (no documented SVA), whereas in the other patient, no 
shocks were documented at the time of a sudden cardiac arrest 
with pulseless electrical activity. He was resuscitated and survived 
the episode. In the entire cohort of 213, 19 patients (including 
the 5 patients described earlier) had an ICD implanted. The total 
time the 19 ICDs were in situ was 71 years (range 0.1–9.3 years 
per patient).
Myocardial infarction
MI occurred in 22 patients. MI event rate was 5.2 in men with 
classical FD, 3.1 in women with classical FD and 3.4 in men with 
non- classical FD. The median EVS was not significantly different 
between the three affected patient groups, although the KM 
Table 3 Firth’s penalised Cox regression

































































coeff, coefficient; CVD, cardiovascular death; HF, heart failure; MACE, major 
adverse cardiovascular event; MI, myocardial infarction; SVA, sustained ventricular 
arrhythmia.
Table 4 HRs for the comparison of different patient groups
Comparison MACE CVD HF SVA MI
Men with classical FD versus men with non- classical FD 6.1 (2.4–17.0)* 22.2 (5.0–19.3)* 15.5 (3.7–82.7)* 5.1 (0.9–41.1) 3.1 (1.0–11.7)
Men with classical FD versus women with classical FD 5.0 (2.3–11.0)* 14.8 (4.3–67.0)* 15.4 (4.1–73.8)* 10.7 (1.9–92.0)* 2.5 (1.0–6.7)
Men with non- classical FD versus women with classical FD 0.8 (0.3–2.0) 0.7 (0.1–2.7) 1 (0.3–3.4) 2.1 (0.4–13.0) 0.8 (0.2–2.4)
These HRs where obtained from Firth’s penalised COX regression models in which sex and phenotype where combined in one variable with four patient groups.
*P<0.008.
CVD, cardiovascular death; FD, Fabry disease; HF, heart failure; MACE, major adverse cardiovascular event; MI, myocardial infarction; SVA, sustained ventricular arrhythmia.
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curves do show a similar pattern as seen for the other cardiac 
events (figure 4D and online supplemental figure 6). A classical 
phenotype increased the risk of MI, but this effect did not hold 
after correcting for multiple testing (table 3). Group compari-
sons showed no significant differences in the HRs between the 
patient groups (table 4; for further MI classification, see online 
supplemental table 3). Cardiovascular risk factors (obesity, 
smoking, hypertension, dyslipidaemia and diabetes mellitus) in 
patients suffering from an MI were present in 4 out of 8 men 
with classical FD (data not available for two patients), in 8 out 
of 10 women with classical FD and in 4 out of 4 men with non- 
classical FD (data not shown).
Data on other non- major cardiac events can be found in the 
online supplemental results section.
DISCUSSION
This is the first longitudinal study that describes the prevalence 
and timing of cardiac events in a large cohort of male and female 
patients with FD, categorised into classical and non- classical 
patient groups. The results show that these sex- defined and 
phenotype- defined patient groups differ substantially in terms of 
their risk of major cardiac events. The risk for all events showed 
the same trend: highest in men with a classical FD, intermediate 
in women with classical FD and in men with non- classical FD, 
and low in women with non- classical FD. For the individual 
events, differences between the groups were not always signifi-
cant due to the relative low event rate. In men with classical FD, 
events occurred mainly from the fifth decade of life onwards, 
resulting in a reduced life expectancy (no men with classical FD 
in our cohort survived beyond 66 years of age). In women with 
classical FD and men with non- classical FD, events are observed 
from the sixth decade onwards, with more variability regarding 
the age of onset. MI is the first major adverse cardiac event 
observed in 21/38 (55%) of patients with a MACE. Most likely, 
both macrovascular and microvascular CADs contribute to the 
development of ischaemia due to endothelial dysfunction and 
cardiac hypertrophy in FD.17 27 28 The relative contribution of 
FD- related endothelial pathology and hypertrophy versus that 
of general risk factors (eg, smoking) cannot easily be determined, 
given that the majority of patients had cardiovascular risk factors 
at the time of MI.
Importantly, none of the women with non- classical FD devel-
oped a MACE. This variation means that if ‘cardiac events’ is a 
clinical endpoint in an FD treatment study, men with classical 
FD should be treated as a separate group from women with 
classical FD and men with non- classical FD, and women with 
non- classical FD should not be included at all. This also means 
that results from previous clinical trials, in which phenotypical 
distinction was not made, should be interpreted with caution.
Figure 4 Kaplan- Meier curves (with 95% CIs) including data of 213 patients with FD, stratified by sex and phenotype for (A) cardiovascular death, 
(B) heart failure hospitalisation, (C) sustained ventricular arrhythmias and (D) myocardial infarction. Patients are censored if the event did not occur 
at the time of the last follow- up contact. Median event- free survival is given for each group in which events occurred. Pairwise comparisons between 
patient groups are given for each cardiac outcome. FD, Fabry disease.
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Fabry cardiomyopathy is associated with a risk of SCD, and in 
advanced disease, ICD implantation should be considered.15 29 
The most frequently observed cause of death in the current study 
was HF (42% of all deaths), whereas SCD comprised 17% of all 
deaths. This finding is in contrast with a recent meta- analysis of 
Baig et al, which identified SCD as the most common cause of 
death (62% of all deaths). However, the context of SCD and the 
FD phenotype of the included patients were not clear for most 
studies included in this meta- analysis. In addition, most included 
studies were performed in small cohorts, with a relatively short 
follow- up duration. In our patients with FD cohort, the SVA rate 
was low and more than half of the patients developed their first 
event in the context of either an MI or HF (hospitalisation or 
ejection fraction<35%). An earlier study of Vijapurapu et al29 
reported a higher event rate in patients with FD with an ICD, but 
sex and phenotype distributions in this group were not reported. 
Large multicentre cohort studies are needed to develop an FD 
SCD risk calculator to guide ICD implantation decision making.
Our findings, if confirmed in other longitudinal cohort studies, 
may change decision making regarding ICD implantation policy 
in FD. With the knowledge that HF is the main contributor 
to death in FD, future studies should aim to detect and treat 
HF in a much earlier phase of the disease. This highlights the 
urgent need for biomarkers that predict future development of 
HF, separating low- risk and high- risk patients, as clearly not all 
women with classical FD and men with non- classical FD develop 
HF.
A limitation of the current study is its retrospective design, 
which may lead to under- recording and subsequent underesti-
mation of the event risk, even though we accessed historical files 
for the majority of patients. Nevertheless, we cannot rule out 
that for some deceased patients, especially those who died over a 
decade ago, some cardiac events may have been missed. In addi-
tion, the reported age of onset of cardiac manifestations such as 
systolic dysfunction, LVOT obstruction and heart valve disease 
depends on the time at which imaging was performed and may 
thus not be fully accurate. The contribution of enrolment bias 
on the observed outcomes between sexes remains unknown. 
In theory, more women could have been identified through 
family screening and more men because of clinical manifesta-
tions, which could have contributed to the observed differences 
in the occurrence of cardiac events. The influence of chronic 
kidney disease on MACE occurrence, which may have increased 
the risk, was not analysed as the sample size and differences in 
follow- up duration between patients did not allow for this anal-
ysis. However, a glomerular filtration rate below 60 mL/min was 
present only in 20% of classically affected male patients and only 
in a single patient from other groups (online supplemental table 
4). In addition, the effect of ERT on the occurrence of cardiac 
events was not analysed, because of the same reasons, as well as 
variability in the age of therapy initiation and indication bias for 
start of treatment.
An important strength of the study is the fact that it was a 
long- term longitudinal study on a large FD cohort, and the 
detailed data on predefined clinical cardiac events, in contrast to 
earlier studies, which often used composites for cardiac involve-
ment in FD, including symptoms of angina pectoris, palpitations 
and microscopic Gb3 storage.22 23
CONCLUSIONS
This large longitudinal study confirms that men with clas-
sical FD develop severe cardiac events, mainly from the fifth 
decade of life onwards. For women with classical FD and men 
with non- classical FD, cardiac events occur approximately a 
decade later and in a smaller proportion of patients. None of 
the non- classically affected women in this cohort developed a 
major cardiac event. More than half of the first observed SVAs 
occurred in the context of either an MI or HF, and HF was the 
most common cause of death. These findings shed new light on 
the clinical course and cardiac outcomes in FD cardiomyopathy 
and emphasise the need for new treatments, primarily to prevent 
HF in FD.
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Key messages
What is already known on this subject?
 ► Early cardiac manifestations of Fabry disease (FD) are 
left ventricular hypertrophy, fibrosis formation and 
conduction abnormalities. As the disease progresses, cardiac 
complications, such as arrhythmias and heart failure (HF), 
occur in a significant proportion of patients with FD, yet 
others remain asymptomatic throughout long- term follow- 
up. The evolution of cardiac events and the influence of sex 
and disease phenotypes on this trajectory have not been 
described previously.
What might this study add?
 ► This is the first large longitudinal cohort study describing 
the effect of disease phenotype and sex on the occurrence 
of cardiac events in FD. The event rates of major adverse 
cardiovascular events (combined endpoint cardiovascular 
death (CVD), HF hospitalisation, sustained ventricular 
arrhythmias (SVA) and myocardial infarction) were 11.0 
in men with classical FD (95% CI 6.6 to 17.3) (event- free 
survival (EVS) 55 years), 4.4 (95% CI 2.5 to 7.1) and in 
women with classical FD (EVS 70 years) and 5.9 (2.6–11.6) 
in men with non- classical FD (EVS 70 years). None of these 
events occurred in women with non- classical FD. CVD was 
the leading cause of death (75%), to which HF contributed 
most (42%). The overall rate of SVAs was low (14 events in 
nine patients (4%))
How might this impact on clinical practice?
 ► Cardiac care in FD should be tailored to the sex and disease 
phenotypes of the patient and should focus on early 
detection and treatment of HF.
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